Correlations between α-synuclein and the AD biomarkers Aβ42, t-tau and p-tau in synucleinopathy patients have lately been investigated and the combination of CSF α-synuclein, tau and Aβ1–42 have shown promising results for facilitated discrimination of synucleinopathy [13], [48], [49], [50]. The gene discussed is MAPT; the disease is Alzheimer disease.